TCGA-56-8626-01A-11R-2403-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.490
- ANGIOGENESIS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- MYOGENESIS+0.360
- HEDGEHOG_SIGNALING+0.340
- TGF_BETA_SIGNALING+0.310
- UV_RESPONSE_DN+0.280
- APICAL_JUNCTION+0.270
- COAGULATION+0.250
- APICAL_SURFACE+0.220
Top 10 suppressed
- E2F_TARGETS-0.580
- MYC_TARGETS_V1-0.560
- OXIDATIVE_PHOSPHORYLATION-0.500
- G2M_CHECKPOINT-0.480
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_GAMMA_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- MTORC1_SIGNALING-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- FATTY_ACID_METABOLISM-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.911 |
| 2 | s0122297 | — | — | 0.908 |
| 3 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.907 |
| 4 | SRR1313111 | — | A | 0.906 |
| 5 | SRR8613703 | — | D | 0.902 |
| 6 | SRR11296795 | — | — | 0.899 |
| 7 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.889 |
| 8 | MBCProject_0832_T1_RNA | — | A | 0.884 |
| 9 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.881 |
| 10 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |